CDK12/Cyclin K Kinase Assay Kit
The CDK12/CyclinK Kinase Assay Kit is designed to measure CDK12 (cyclin dependent kinase 12)/CyclinK kinase activity for screening and profiling applications using Kinase-Glo™ Max as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant CDK12 (amino acids 696-1082)/CyclinK complex, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.
Need us to run inhibitor screens or profile your compounds against CDK12/Cyclin K? Check out our Kinase Screening Services or DNA Replication and Repair Screening Services.
- Kinase-Glo™ MAX (Promega #V6973)
- DTT (Dithiothreitol), 1M, optional
- Microplate reader capable of reading luminescence
- Adjustable micropipettor and sterile tips
- 30°C incubator
| Catalog # | Name | Amount | Storage |
| 100998 | CDK12 (696-1082)/CyclinK, GST-Tags* | 50 µg | -80°C |
| 79334 | 5x Kinase Buffer 1 | 1.5 ml | -20°C |
| 79686 | 500 µM ATP | 100 µl | -20°C |
| 0.5M DTT | 200 µl | -20°C | |
| 78299 | CDK12/CyclinK Substrate (10 mg/ml) | 200 µl | -20°C |
| 79696 | White 96-well plate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
The CDK12/CyclinK complex comprises human CDK12 (Cyclin dependent kinase 12) and human cyclinK. CDK12 is ubiquitously expressed, being present at high levels in the reproductive tissues, endocrine tissues, bone marrow and lymph nodes, being found predominantly in the nucleus of cells. CDK12 is involved in gene expression, transcription elongation and genome stability. CDK12 binds only to cyclinK, and the formation of this complex seems important to maintain cyclinK stability. This complex regulates phosphorylation of serine 2 in the C-terminal domain of RNA polymerase II, which is responsible for transcriptional elongation and synthesis of full-length mature mRNAs. However, lack of CDK12 seems to only affect about 5% or less of the total transcription, indicating a selective role in the transcription of certain genes. The use of inhibitors, such as THZ531, indicated that the genes being selectively regulated by CDK12/cyclinK are the core DDR (DNA damage and repair) genes. CDK12 plays a role in cancer development such as in breast and prostate cancer. The use of CDK12/cyclinK inhibitors in combination with PARP (poly-(ADP-ribose) protein) inhibitors can increase the response of cells to PARP inhibition and cell death in cases of drug resistance. The development of CDK12 inhibitors, to be used alone or in combination therapy, is a promising field of research in cancer therapy.
Zhang T., et al., 2016 Nat Chem Biol 12, 876–884.
Bösken C.A., et al., 2014 Nat Commun. Mar 24;5:3505.
Choi S., et al., 2020 Experimental & Molecular Medicine 52:762-771.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.